Scientific Online Resource System

Heart - Lung (Varna)

Recommendations for treatment in atrial fibrilation

A. Penev, M. Negreva, A. Angelov, P. Petrov


Atrial fi brillation (AF) is the most common arrhythmia in clinical practice, affecting 1-2 % of the general population (6). In Europe, more than 6 million people suffer from AF and the number is expected to double in the next 50 years (14). In connection with the increased embologenic risk, statistics show that the incidence of stroke in AF is fi ve times higher compared to those in sinus rhythm. Also, every fi fth ischemic stroke is considered to be due to arrhythmia (12). Precisely in these strokes, a large number of relapses and often a fatal outcome are observed. AF increases cardiovascular morbidity and mortality, decreases the exercise capacity and the cognitive function of patients. Therefore the question of heart rhythm control in patients with AF is of major interest to clinical practice.


atrial fi brillation, heart rate control, rhythm control

Full Text


Alboni P, Botto GL, Baldi N, Luzi M, Russo V, Gianfranchi L, Marchi P,Calzolari M, Solano A, Baroffi o R, Gaggioli G. Outpatient treatment of recent-onset atrial fi - brillation with the `pill-in-the-pocket` approach. N Engl J Med 2004; 351:2384-2391.

Bianconi L, Mennuni M, Lukic V, Castro A, Chieffi M, Santini M. Effects of oral propafenone administration before electrical cardioversion of chronic atrial fi brillation: a placebo-controlled study. J Am Coll Cardiol 1996; 28:700-706.

Binici Z, Intzilakis T, Nielsen OW, Kober L, Sajadieh A. Excessive Supraventricular ectopic activity and increased risk of atrial fi brillation and stroke. Circulation 2010; 121:1904-1911.

Camm AJ, Capucci A, Hohnloser S, Torp-Pedersen C, Van Gelder IC, Mangal B, Beatch GN. A randomized active-controlled study comparing the effi cacy and safety of vernakalant to amiodarone in recent onset atrial fi brillation. J Am Coll Cardiol 2010.

Cosio FG, Aliot E, Botto GL, Heidbuchel H, Geller CJ, Kirchhof P, De Haro JC, Frank R, Villacastin JP, Vijgen J, Crijns H. Delayed rhythm control of atrial fi brillation may be a cause of failure to prevent recurrences: reasons for change to active antiarrhythmic treatment at the time of the fi rst detected episode. EuroPace 2008; 10:21-27.

Go, A. S., E. M. Hylek, K. A. Phillips, Y. Chang, L. E. Henault, J. V. Selby, D. E. Singer. Prevalence of diagnosed atrial fi brillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001; 285(18):2370-5.

Hagens V., H. Crijns, D. Van Veldhuisen et al. Rate control versus rhythm control for patients with persistent atrial fi brillation with mild to moderate heart failure: Results from the Race Control versus Electrical cardioversion (RACE) study. Am Heart J 2005; 149:1106-1111.

Khan IA. Single oral loading dose of propafenone for pharmacological cardioversion of recent-onset atrial fi brillation. J Am Coll Cardiol 2001; 37:542-547.

Kirchhof P, Bax J, Blomstrom-Lundquist C, Calkins H, Camm AJ, Cappato R, Cosio F, Crijns H, Diener HC, Goette A, Israel CW, Kuck KH, Lip GY, Nattel S, Page RL, Ravens U, Schotten U, Steinbeck G, Vardas P, Waldo A, Wegscheider K, Willems S, Breithardt G. Early and comprehensive management of atrial fi brillation: executive summary of the proceedings from the 2nd AFNET-EHRA consensus conference `Research perspectives in AF`. Eur Heart J 2009; 30:2969-2977c.

Kirchhof P, Eckardt L, Loh P, Weber K, Fischer RJ, Seidl KH, Bocker D, Breithardt G, Haverkamp W, Borggrefe M. Anterior - posterior versus anterior-lateral electrode positions for external cardioversion of atrial fi brillation: a randomised trial. Lancet 2002; 360:1275-1279.

Kirchhof P. Can we improve outcomes in atrial fi brillation patients by early therapy? BMC Med 2009; 7:72.

Kirchhof, P., A. Auricchio, J. Bax, H. Crijns, J. Camm, et al. Outcome parameters for trials in atrial fi brillation: executive summary. Eur Heart J. 2007; 28(22):2803-17.

Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refi ning clinical risk stratifi cation for predicting stroke and thromboembolism in atrial fi brillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fi brillation. Chest 2010; 137:263-272.

Lip, G., R. Caterina, I. Savelieva, et al. ESC Committee for Practice Guidelines 2012 focused update of the ESC Guidelines for the management of atrial fi brillation. Eur Heart J. (2012); 33:2719-2747.

Manios EG, Mavrakis HE, Kanoupakis EM, Kallergis EM, Dermitzaki DN, Kambouraki DC, Vardas PE. Effects of amiodarone and diltiazem on persistent atrial fi brillation conversion and recurrence rates: a randomized controlled study. Cardiovasc Drugs Ther 2003; 17:31 - 39.

Ogawa S, Yamashita T, Yamazaki T, Aizawa Y, Atarashi H, Inoue H, Ohe T, Ohtsu H, Okumura K, Katoh T, Kamakura S, Kumagai K, Kurachi Y, Kodama I, Koretsune Y, Saikawa T, Sakurai M, Sugi K, Tabuchi T, Nakaya H, Nakayama T, Hirai M, Fukatani M, Mitamura H. Optimal treatment strategy for patients with paroxysmal atrial fi brillation: J-RHYTHM Study. Circ J 2009;73 :242 - 248.

Oral H, Souza JJ, Michaud GF, Knight BP, Goyal R, Strickberger SA, Morady F. Facilitating transthoracic cardioversion of atrial fi brillation with ibutilide pretreatment. N Engl J Med 1999; 340:1849 - 1854.

Roy D.,M. Talajic, S. Nattel et al. Rhythm control versus rate control for atrial fi brillation and heart failure. N Engl J Med 2008; 358:2667-2677.

Segal JB, McNamara RL, Miller MR, Kim N, Goodman SN, Powe NR, Robinson K, Yu D, Bass EB. The evidence regarding the drugs used for ventricular rate control. J Fam Pract 2000; 49:47 - 59.

Steinberg S., A. Sadaniantz, J Kron et al. Analysis of cause-specifi c mortality in the atrial fi brillation follow-up investigation of rhythm management. Circulation 2004; 109:1973-1980.

Van Gelder IC, Hagens VE, Bosker HA, Kingma H, Kamp O, Kingma T, Said SA, Darmanata JI, Timmermanns AJM, Tijssen JGP, Crijns HJ. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fi brillation. N Engl J Med 2002; 347:1834 - 1840.

Van Gelder IC, Groenveld HF, Crijns HJ, Tuininga YS, Tijssen JG, Alings AM, Hillege HL, Bergsma-Kadijk JA, Cornel JH, Kamp O, Tukkie R, Bosker HA, Van Veldhuisen DJ, Van den Berg MP. Lenient versus strict rate control in patients with atrial fi brillation. N Engl J Med 2010; 362:1363 - 1373.

Wyse D., A. L. Waldo. J. P. DiMarco et al. A comparison of rate control and rhythm control in patients with atrial fi brillation. N Engl Med 2002; 143:991-1001.



Font Size